Dermira (DERM) Upgraded at BidaskClub

Dermira (NASDAQ:DERM) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Tuesday, BidAskClub reports.

A number of other brokerages have also issued reports on DERM. Zacks Investment Research lowered Dermira from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Mizuho lifted their target price on Dermira from $10.00 to $17.00 and gave the company a “positive” rating in a research report on Thursday, March 21st. They noted that the move was a valuation call. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 target price on shares of Dermira in a research report on Tuesday, April 2nd. HC Wainwright started coverage on Dermira in a research report on Thursday, February 14th. They issued a “buy” rating and a $13.00 target price on the stock. Finally, Leerink Swann started coverage on Dermira in a research report on Friday, February 22nd. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.30.

NASDAQ DERM opened at $10.31 on Tuesday. The stock has a market cap of $551.73 million, a PE ratio of -1.97 and a beta of 1.32. The company has a current ratio of 7.13, a quick ratio of 6.92 and a debt-to-equity ratio of 4.36. Dermira has a one year low of $6.00 and a one year high of $15.48.

Dermira (NASDAQ:DERM) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.39). Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. The firm had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.63 million. Research analysts anticipate that Dermira will post -5.21 earnings per share for the current fiscal year.

In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the transaction, the insider now directly owns 43,900 shares in the company, valued at $658,500. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.80% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of DERM. Fifth Third Bancorp bought a new position in Dermira in the first quarter valued at approximately $44,000. Advisor Group Inc. grew its stake in Dermira by 117.0% in the first quarter. Advisor Group Inc. now owns 6,062 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 3,269 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its stake in Dermira by 356.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 10,085 shares in the last quarter. Jane Street Group LLC bought a new position in Dermira in the fourth quarter valued at approximately $95,000. Finally, BNP Paribas Arbitrage SA grew its stake in Dermira by 48,273.3% in the first quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 7,241 shares in the last quarter. Hedge funds and other institutional investors own 68.70% of the company’s stock.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Recommended Story: What is Call Option Volume?

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.